News Details

Contact

Rachel Darwin, Senior Manager, Public Relations

darwin@nccn.org, 2676226624

Kimary Kulig, PhD, MPH Joins NCCN Staff as Vice President, Clinical & Translational Outcomes Research


NCCN welcomes Kimary Kulig, PhD, MPH as Vice President, Clinical & Translational Outcomes Research. Among her responsibilities, Dr. Kulig will oversee the NCCN Oncology Outcomes Database that serves both as a major clinical research repository and an analytical reporting system developed to evaluate NCCN Member Institution concordance of practice to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™).


FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) is pleased to welcome Kimary Kulig, PhD, MPH, as Vice President, Clinical & Translational Outcomes Research. Dr. Kulig`s primary responsibility is to direct the ongoing development and advancement of the NCCN Oncology Outcomes Database (NCCN Database). The NCCN Database is a set of databases on five major tumor types with comprehensive data, including clinical outcomes, on thousands of patients treated at NCCN Member Institutions

We are excited to have Dr. Kulig, an internationally recognized expert and an experienced leader in oncology-specific outcomes research, join our staff as we look to advance the utility and productivity of the NCCN Database, said William T. McGivney, PhD, CEO of NCCN. Her extensive experience in leading oncology research programs combined with her background in biomedical research and years in the public health sector make her an ideal fit for the NCCN.

Prior to joining NCCN, Dr. Kulig worked for several years leading outcomes based research in oncology at Pfizer, Inc., most recently as Senior Director and Lead, Molecular Epidemiology Research, Oncology. In this role, Dr. Kulig designed and conducted biomarker-linked outcomes research projects in support of multiple clinical development programs, including those involving companion diagnostics, at the global level.

Prior to Dr. Kulig`s appointment at Pfizer, Inc., she led an epidemiology and surveillance research program for the Arthritis Foundation, conducted public health research at Columbia University Mailman School of Public Health and the Centers for Disease Control and Prevention (CDC), and engaged in immunology research at Columbia University`s College of Physicians and Surgeons, the Kennedy Institute of Rheumatology (London, England), and the Mayo Clinic (Rochester, MN).

Dr. Kulig holds a masters degree in public health with an emphasis in epidemiology from Columbia University Mailman School of Public Health and earned her doctorate in immunology and molecular oncology from the New York University School of Medicine.

The NCCN Database is a network-based data collection, reporting, and analytic system that describes the patterns and outcomes of care delivered in the management of patients with cancer. With the NCCN Database, NCCN seeks to implement the NCCN Guidelines™ through performance measurement. The NCCN Database is a component of NCCN Insights: Analytics, Research & Consulting. Through several tools and services, NCCN provides insight, research, and analysis on oncology patterns of care and key clinical and outcomes issues in the cancer environment.